Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.
Aweeka
F T
FT
Division of Clinical Pharmacy, University of California, San Francisco 94143-0622.
Gambertoglio
J G
JG
van der Horst
C
C
Raasch
R
R
Jacobson
M A
MA
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000378:metabolism*; D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D017245:Foscarnet / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016655:HIV Core Protein p24 / Q000032:analysis / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000998:Antiviral Agents; D016655:HIV Core Protein p24; D017245:Foscarnet; D015215:Zidovudine